J
Jana Markova
Researcher at Charles University in Prague
Publications - 97
Citations - 3144
Jana Markova is an academic researcher from Charles University in Prague. The author has contributed to research in topics: BEACOPP & ABVD. The author has an hindex of 22, co-authored 86 publications receiving 2690 citations. Previous affiliations of Jana Markova include Czech Hydrometeorological Institute.
Papers
More filters
Journal ArticleDOI
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Andreas Engert,Heinz Haverkamp,Carsten Kobe,Jana Markova,Christoph Renner,A. D. Ho,Josée M. Zijlstra,Zdenek Kral,Michael Fuchs,Michael Hallek,Lothar Kanz,Hartmut Döhner,Bernd Dörken,Nicole Engel,Max S. Topp,Susanne Klutmann,Holger Amthauer,Andreas Bockisch,Regine Kluge,Clemens Kratochwil,Otmar Schober,Richard Greil,Reinhard Andreesen,Michael Kneba,Michael Pfreundschuh,Harald Stein,Hans Theodor Eich,Rolf-Peter Müller,Markus Dietlein,Peter Borchmann,Volker Diehl +30 more
TL;DR: Treatment with six cycles of BEACOPP(escalated) followed by PET-guided radiotherapy was more effective in terms of freedom from treatment failure and less toxic than eight cycles of the same chemotherapy regimen, and should be the treatment of choice for advanced stage Hodgkin's lymphoma.
Journal ArticleDOI
Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
Hans Theodor Eich,Volker Diehl,Helen Görgen,Thomas Pabst,Jana Markova,Jürgen Debus,Anthony D. Ho,Bernd Dörken,Andreas Rank,Anca-Ligia Grosu,Thomas Wiegel,Johann H. Karstens,Richard Greil,Normann Willich,Heinz Schmidberger,Hartmut Döhner,Peter Borchmann,Hans Konrad Müller-Hermelink,Rolf-Peter Müller,Andreas Engert +19 more
TL;DR: Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL, and four cycles of ABVD should be followed by 30 Gy of IFRT.
Journal ArticleDOI
Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
Bastian von Tresckow,Annette Plütschow,Michael Fuchs,Beate Klimm,Jana Markova,Andreas Lohri,Zdenek Kral,Richard Greil,Max S. Topp,Julia Meissner,Josée M. Zijlstra,Martin Soekler,Harald Stein,Hans Theodor Eich,Rolf P. Mueller,Volker Diehl,Peter Borchmann,Andreas Engert +17 more
TL;DR: Intensified chemotherapy with two cycles of BEACOPP escalated followed by three cycles of ABVD followed by IFRT significantly improves tumor control in patients with early unfavorable HL.
Journal ArticleDOI
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Peter Borchmann,Helen Goergen,Carsten Kobe,Andreas Lohri,Richard Greil,Dennis A. Eichenauer,Josée M. Zijlstra,Jana Markova,Julia Meissner,Michaela Feuring-Buske,Andreas Hüttmann,Judith Dierlamm,Martin Soekler,Hans Joachim Beck,Wolfgang Willenbacher,Wolf-Dieter Ludwig,Thomas Pabst,Max S. Topp,Felicitas Hitz,Martin Bentz,Ulrich Keller,Dagmar Kühnhardt,Helmut Ostermann,Norbert Schmitz,Bernd Hertenstein,Walter E. Aulitzky,Georg Maschmeyer,Tom Vieler,Hans Theodor Eich,Christian Baues,Harald Stein,Michael Fuchs,Georg Kuhnert,Volker Diehl,Markus Dietlein,Andreas Engert +35 more
TL;DR: This open-label, randomised, parallel-group phase 3 trial investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it forPET- 2-negative patients and showed non-inferiority in the 5-year progression-free survival estimates.
Journal ArticleDOI
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe,Markus Dietlein,Jeremy Franklin,Jana Markova,Andreas Lohri,Holger Amthauer,Susanne Klutmann,Wolfram H. Knapp,Josée M. Zijlstra,Andreas Bockisch,Matthias Weckesser,Reinhard Lorenz,Mathias Schreckenberger,Roland Bares,Hans Theodor Eich,Rolf-Peter Mueller,Michael Fuchs,Peter Borchmann,Harald Schicha,Volker Diehl,Andreas Engert +20 more
TL;DR: Responsible response adapted therapy guided by PET for HL patients seems to be a promising approach that should be further evaluated in clinical trials.